Specifically, FTO is targeted by bisantrene for acute myeloid leukemia (Phase II), and GRM2 is targeted by four investigational drugs for central nervous system disorders including schizophrenia, major depressive disorder, perceptual disorders, bipolar disorder, psychosis, methamphetamine dependence, post-traumatic stress disorder, and seizure disorder. This evidence concerns the gene FTO and bipolar disorder.